Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Promoting excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Paulus Kirchhof,
Prof. Gregory Y. H. Lip
Presenter abstractDiscussant reportAll the Scientific resources on ESC Congress 365
By Gregory Y H LipOther authors: Dr Dierdre A Lane, United Kingdom; Dr Harry Buller, Netherlands; Dr Stavros Apostolakis, United KingdomBackground:Given the overlap between stroke and bleeding risk factors, a risk stratification score for thromboembolism and serious bleeding could potentially be developed for patients with atrial fibrillation (AF). It is uncertain if such a composite score offers better predictive value or practical application against existing individual stroke and bleeding scores.
Methods:We used data from the vitamin K antagonist (VKA) arm of the AMADEUS trial, which was a multicentre, randomised, non-inferiority study that compared fixed-dose idraparinux with VKA in AF patients. We assessed predictors of outcome using two composite endpoints: Endpoint 1 was the sum of stroke or non-CNS systemic embolism and major bleeding. Endpoint 2 was defined as the sum of stroke, systemic or venous embolism, myocardial infarction, cardiovascular death or major bleeding.
Results:The AMADEUS study randomized 2293 patients to the VKA arm. In a binary logistic regression analysis the independent predictors for composite endpoint 1 (50 events; 2.4/100 patient-years), were age (p=0.014), previous stroke/TIA (p=0.049), aspirin use (p=0.002) and time in therapeutic range (p=0.007). For the composite endpoint 2 (94 events; 4.5/100 patient-years), similar predictors were evident, plus left ventricular systolic dysfunction (p=0.011). We used these factors to develop scores by applying weight for each variable relative to the magnitude of the regression coefficients. Composite score 1 = (0.05 x Age)+(0.6 x Previous stroke or TIA)+(0.9 x concomitant aspirin)-(1.8 x TTR)Composite score 2 = (0.05 x Age)+(0.6 x Previous stroke or TIA)+(0.7 x concomitant aspirin)+(0.6 x LV dysfunction)-(1.4 x TTR)The weighted scores (composite scores 1 and 2) demonstrated the highest numerical discriminatory performance (AUC=0.728; 95%CI: 0.659-0.798 and AUC=0.707; 95%CI: 0.655-0.758, for the endpoints 1 and 2 respectively), and positive net reclassification compared to all other scores. The predictive or practical clinical utility of these new scores, when compared to the use of existing individual stroke and bleeding risk scores will be presented for the first time at the ESC meeting.Conclusion:We have developed and validated a novel composite score for stroke/thromboembolism/bleeding. Whilst individual risk stratification with existing stroke and bleeding scores would allow personalized balancing of the risk of stroke/thromboembolism against serious bleeding, the value of this composite score merits further study.
Francisco MarinAtrial fibrillation (AF) is associated with increased risk of stroke and thromboembolism, and thus oral anticoagulation (OAC) therapy is indicated in patients considered at moderate-to-high risk. The 2012 European Society of Cardiology (ESC) guidelines recommend the CHA2DS2-VASc score for stroke risk stratification in patients with AF, whereby following the initial identification of ‘truly low risk’ patients, those with ≥1 stroke risk factors can be offered effective stroke prevention, which is OAC.
The use of OAC is associated with an increased risk of major bleeding, with intracranial haemorrhage being the fearest complication associated with warfarin. The HAS-BLED bleeding risk score is the recommended score in the ESC guidelines as a practical tool to assess the individual bleeding risk in AF patients, whereby a score of ≥3 indicates ‘high risk’1. These risk stratification scales have been validated in different clinical scenarios, and have a potential role predicting different end-points, as all-cause death or other thrombotic complications, i.e. myocardial infarction.
The net clinical benefit favours anticoagulation for almost all AF patients with the exception of those at very low risk of ischemic stroke, essentially those with a CHA2DS2-VASc score of 0. Based on the results of a real-world nationwide cohort study of patients with non-valvular AF, the net clinical benefit was clearly in favour of VKA treatment in AF patients with increased risk of stroke/thromboembolism, regardless of bleeding risk estimation (as assessed by the HAS-BLED risk score).
In the present Clinical Trial Update, Lip et al. explore an interesting question, to create a composite risk score to assess the overall clinical outcome in AF, considering both stroke/thromboembolism and/or serious bleeding. They tested two composite clinical endpoints, that is:(i) thromboembolism/major bleeding (a simple composite, Endpoint 1), and(ii) stroke, systemic or venous embolism, myocardial infarction, cardiovascular death and major bleeds (a more complex composite, Endpoint 2). The study of Lip et al was based on a study population of 2,293 patients in the VKA arm of the AMADEUS trial.
The authors found that the independent predictors for Endpoint-1 were age, previous stroke/TIA, aspirin use and time in therapeutic range (TTR); and for Endpoint-2 were the same predictors plus left ventricular dysfunction. Based on this, two new composite risk scores were developed, which both offer good discriminative and predictive performance. However, when the authors compared these new composite scores to the established risk scores, that is CHADS2, CHA2DS2-VASc or HAS-BLED, there were no significant improvements in the endpoint predictions.
The strengths of the study of Professor Lip et al. are remarkable
The findings of the present study should be interpreted in the setting of the study design and its limitations, as the authors recognise. The authors included patients from a clinical trial, with their inherent limitations. All the patients were taking OAC, and we need to understand the global risk of our patients, with or without OAC. When considering the balance of risk and benefit, not every major complication (major bleeding, embolism, cardiac events) can be weighted equally, and patient’s values and preferences also should be considered.
In conclusion, whilst Lip et al are to be commended for having validated 2 novel composite scores for stroke/thromboembolism/bleeding that offer good discriminatory and predictive performance, these composite risk scores did not perform better than the easier and more user-friendly ‘classical’ stroke and bleeding risk scores that are currently in use. Existing risk scores for stroke and bleeding separately offer far greater practically, and more personalised balancing of risks, as well as simplicity.
Conflicts of interestDr. Marín has received research grants from and served in the speakers bureau of Bayer, Boehringer-Ingelheim and Pfizer/BMS.
AMADEUS: Development of a novel composite stroke and bleeding risk score in patients with atrial fibrillation